A previous study on breast cancer demonstrated that silibinin treatment impairs mitochondrial dynamics, decreases ROS levels, and prevents NLRP3 inflammasome activation in MDA-MB-231 cells [56]. The gene discussed is NLRP3; the disease is breast cancer.